Not provided
Not provided
Not provided
Not provided
Not provided
Lack of efficacy based on the interim analysis in the 17972A study
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lu AF11167 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lu AF11167 | Drug | Lu AF11167 - 2 or 4 mg/day; tablets, orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with Treatment-Emergent Adverse Events | Safety and Tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, BMI, waist, weight, ECG parameters) | From baseline week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Brief Negative Symptom Scale (BNSS) total score | The BNSS is a brief clinician rating scale, intended to measure negative symptoms. It consists of 13 items organized into 6 subscales: anhedonia, distress, asociality, avolition, blunted affect, and alogia. The items score the impairment. Items 1 to 4 are rated from 0 (Normal) to 6 (Extremely severe) and items 5 to 13 are rated from 0 (No impairment) to 6 (Severe deficit). The BNSS total score is calculated by summing the 13 individual items; subscale scores are calculated by summing the individual items within each subscale. Users of the BNSS should have training in psychiatric interview techniques and have clinical experience working with patients with schizophrenia and related psychotic disorders. The BNSS total scores ranges from 0 to 78. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other in- and exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Email contact via H. Lundbeck A/S | LundbeckClinicalTrials@Lundbeck.com | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mental Health Center Prof. Dr. Ivan Temkov EOOD (BG0001) | Burgas | Bulgaria | ||||
| MHAT Dr. Hristo Stambolski (BG0007) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35704951 | Derived | Meyer-Lindenberg A, Nielsen J, Such P, Lemming OM, Zambori J, Buller R, der Goltz CV. A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia. Eur Neuropsychopharmacol. 2022 Aug;61:4-14. doi: 10.1016/j.euroneuro.2022.05.009. Epub 2022 Jun 12. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| from baseline to Week 24 |
| Change in Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptoms Factor Score | The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items: 7 items make up the positive scale (for example: delusions, conceptual disorganization and hallucinatory behaviour), 7 items make up the negative scale (for example: blunted affect, emotional withdrawal and poor rapport) and 16 items make up the general psychopathology scale (for example: somatic concern, anxiety and guilt feelings). Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). The PANSS total score is the sum of all items, and ranges from 30 to 210. Subscale scores are the sum of items within each subscale. | from baseline to Week 24 |
| Change in PANSS Negative subscale score | The PANSS is a clinician rated scale designed to measure severity of psychopathology in adult patients with schizophrenia, schizoaffective disorders and other psychotic disorders. It emphasizes positive and negative symptoms. The PANSS includes 3 sub-scales and 30 items: 7 items make up the positive scale (for example: delusions, conceptual disorganization and hallucinatory behaviour), 7 items make up the negative scale (for example: blunted affect, emotional withdrawal and poor rapport) and 16 items make up the general psychopathology scale (for example: somatic concern, anxiety and guilt feelings). Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). The PANSS total score is the sum of all items, and ranges from 30 to 210. Subscale scores are the sum of items within each subscale. | from baseline to Week 24 |
| Change in CGI-SCH-S negative symptoms score | The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive, and depressive) and the overall severity of the disorder. The CGI-SCH-severity of illness symptoms and overall severity are rated on a 7-point scale ranging from 1 (normal - not ill) to 7 (Among the most severely ill). For the first four ratings (positive, negative, depressive, and cognitive symptoms), the assessment should focus on the severity of symptoms only. Additionally, for 'overall severity' rating, both severity of symptoms and interference with functioning should be considered. | from baseline to Week 24 |
| CGI-SCH-DC negative symptoms score | The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive, and depressive) and the overall severity of the disorder. The CGI-SCH-degree of change symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of change) and overall ratings of severity and improvement are scored independently and no total score is derived. | at Week 24 |
| CGI-SCH-DC negative symptoms response | The CGI-SCH is a clinician-rated scale to assess global illness severity and degree of change in patients with schizophrenia. For both the global illness severity and degree of change, the CGI-SCH consists of four different groups of symptoms (positive, negative, cognitive, and depressive) and the overall severity of the disorder. The CGI-SCH-degree of change symptoms and overall severity are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Each single rating (conditions of severity and degree of change) and overall ratings of severity and improvement are scored independently and no total score is derived.CGI-SCH-DC negative symptoms response is defined as a CGI-SCH-DC negative symptoms score of 1 or 2. | at Week 24 |
| Kazanlak |
| Bulgaria |
| First Department for men with acute mental diseases-NPH Sv. Ivan Rilski (BG0010) | Novi Iskar | Bulgaria |
| UMHAT Dr.Georgi Stranski EAD (BG0006) | Pleven | 5800 | Bulgaria |
| State Psychiatric Hospital - Sevlievo (BG0009) | Sevlievo | 5400 | Bulgaria |
| Medical Center INTERMEDICA (BG0003) | Sofia | Bulgaria |
| DCC Mladost-M (BG0004) | Varna | 9000 | Bulgaria |
| Med Centre Medical plus (BG0008) | Varna | 9000 | Bulgaria |
| DCC Mladost-M Varna OOD (BG0005) | Varna | Bulgaria |
| Mental Health Center-Vratsa EOOD (BG0002) | Vratsa | Bulgaria |
| Marienthali Kliinik (EE0001) | Tallinn | Estonia |
| OU Jaanson & Laane (EE0002) | Tartu | Estonia |
| Office of Dr.Kirsten Hahn MD (DE0002) | Berlin | Germany |
| Semmelweis Egyetem Neurologiai Klinika-Semmelweis University (HU0005) | Budapest | 1083 | Hungary |
| Bugat Pal Hospital (HU0008) | Gyöngyös | 3200 | Hungary |
| Dr Mathe es Tarsa Bt (HU0001) | Kalocsa | Hungary |
| Javorszky Odon Hospital (HU0004) | Vác | Hungary |
| Hospital Gintermuiza (LV0001) | Jelgava | Latvia |
| Riga Centre Of Psychiatry And Addiction Disorders (LV0002) | Riga | Latvia |
| Sigulda Hospital Outpatient Clinic (LV0006) | Sigulda | Latvia |
| Syntonia Sp. z o.o. (PL0002) | Pruszcz Gdański | 83000 | Poland |
| Si Inpn Namsu (Ua0003) | Kharkiv | 61068 | Ukraine |
| Si Inpn Namsu (Ua0008) | Kharkiv | Ukraine |
| Kherson Regional Psychiatric Hospital (UA0009) | Kherson | Ukraine |
| Kiev Regional Specialized Psycho-Narcological Medical Care (UA0005) | Kiev | Ukraine |
| Regional Clinical Psychiatry Hospital of Kirovograd Regional Council, Donetsk National Medical University (UA0004) | Kropyvnytskyi | Ukraine |
| "Kyiv Railway Clinical Hospital ¿1 of Branch ""Health Center"" of the Public joint stock company ""Ukrainian Railway"", psychoneurological department" (UA0007) | Kyiv | 1030 | Ukraine |
| Odessa Regional Medical Centre of Mental Health (UA0006) | Odesa | Ukraine |
| Ukrainian Medical Stomatological Academy (UA0001) | Poltava | Ukraine |
| Vinnitsa National Medical University (UA0002) | Vinnytsia | Ukraine |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided